Journal of Clinical Oncology, Vol 15, 2559-2563, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival

JA McCaffrey, M Mazumdar, DF Bajorin, GJ Bosl, V Vlamis and RJ Motzer
Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY 10021, USA. mccaffrj@mskcc.org

PURPOSE: To evaluate the efficacy and toxicity of ifosfamide- and cisplatin-containing chemotherapy as first-line salvage treatment for patients with germ cell tumors (GCT). PATIENTS AND METHODS: Fifty-six patients with advanced GCT resistant to one prior cisplatin-containing regimen were treated with a salvage chemotherapy regimen of ifosfamide, cisplatin, and either vinblastine or etoposide (VeIP/VIP). RESULTS: Twenty of 56 (36%) assessable patients achieved a complete response (CR). Thirteen (23%) are alive and continuously free of disease at a median follow-up time of 52 months; the median survival duration was 18 months. Among patients with a testis primary tumor site and a prior CR to first-line therapy, 65% are alive and 41% continuously disease-free, and the median survival time has not been reached. In contrast, for patients with an extragonadal primary tumor or with a testis primary tumor site and an incomplete response (IR) to first-line therapy, 31% are alive and 15% continuously free of disease, with a median survival time of 12 months (P < .03). CONCLUSION: Ifosfamide- and cisplatin- containing therapy achieves a durable CR in a minority of patients with resistant GCT as first-line therapy. Patients with a primary testis site who relapsed from a CR to first-line cisplatin therapy have a better prognosis than patients with an extragonadal primary tumor site or an IR to first-line therapy. Risk-directed clinical trials to improve response and survival in both subsets are warranted.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Tanaka, H. Kitamura, A. Takahashi, N. Masumori, and T. Tsukamoto Long-term Outcome of Chemotherapy for Advanced Testicular and Extragonadal Germ Cell Tumors: A Single-center 27-year Experience Jpn. J. Clin. Oncol., September 22, 2009; (2009) hyp121v1. [Abstract] [Full Text] [PDF]

				D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]

				A. J. Stephenson, G. J. Bosl, R. J. Motzer, D. F. Bajorin, J. P. Stasi, and J. Sheinfeld Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer J. Clin. Oncol., December 10, 2007; 25(35): 5597 - 5602. [Abstract] [Full Text] [PDF]

				D. M. Gershenson Management of Ovarian Germ Cell Tumors J. Clin. Oncol., July 10, 2007; 25(20): 2938 - 2943. [Abstract] [Full Text] [PDF]

				G. Sonpavde, T. E. Hutson, and B. J. Roth Management of Recurrent Testicular Germ Cell Tumors Oncologist, January 1, 2007; 12(1): 51 - 61. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta and R. J. Motzer Chemotherapy for Advanced Germ Cell Tumors J. Clin. Oncol., December 10, 2006; 24(35): 5493 - 5502. [Abstract] [Full Text] [PDF]

				J. Oldenburg, J. M. Martin, and S. D. Fossa Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis J. Clin. Oncol., December 10, 2006; 24(35): 5503 - 5511. [Abstract] [Full Text] [PDF]

				K. Kawai, S. Ando, S. Hinotsu, T. Oikawa, N. Sekido, N. Miyanaga, T. Shimazui, and H. Akaza Completion and Toxicity of Induction Chemotherapy for Metastatic Testicular Cancer: An Updated Evaluation of Japanese Patients Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 425 - 431. [Abstract] [Full Text] [PDF]

				E. A. Ronnen, G. V. Kondagunta, J. Bacik, S. Marion, D. F. Bajorin, J. Sheinfeld, G. J. Bosl, and R. J. Motzer Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy J. Clin. Oncol., October 1, 2005; 23(28): 6999 - 7004. [Abstract] [Full Text] [PDF]

				G. V. Kondagunta, J. Bacik, A. Donadio, D. Bajorin, S. Marion, J. Sheinfeld, G. J. Bosl, and R. J. Motzer Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors J. Clin. Oncol., September 20, 2005; 23(27): 6549 - 6555. [Abstract] [Full Text] [PDF]

				J.-P. Lotz, B. Bui, F. Gomez, C. Theodore, A. Caty, K. Fizazi, G. Gravis, R. Delva, J. Peny, P. Viens, et al. Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial Ann. Onc., March 1, 2005; 16(3): 411 - 418. [Abstract] [Full Text] [PDF]

				R. J. Motzer and J. Sheinfeld Poor-Risk Testicular Cancer and High-Dose Chemotherapy J. Clin. Oncol., November 15, 2003; 21(22): 4073 - 4074. [Full Text] [PDF]

				J. Miyazaki, K. Kawai, H. Hayashi, M. Onozawa, S. Tsukamoto, N. Miyanaga, S. Hinotsu, T. Shimazui, and H. Akaza The Limited Efficacy of Methotrexate, Actinomycin D and Cisplatin (MAP) for Patients with Advanced Testicular Cancer Jpn. J. Clin. Oncol., August 1, 2003; 33(8): 391 - 395. [Abstract] [Full Text] [PDF]

				K. Kawai, J. Miyazaki, S. Tsukamoto, S. Hinotsu, K. Hattori, T. Shimazui, and H. Akaza Paclitaxel, Ifosfamide and Cisplatin Regimen is Feasible for Japanese Patients with Advanced Germ Cell Cancer Jpn. J. Clin. Oncol., March 1, 2003; 33(3): 127 - 131. [Abstract] [Full Text] [PDF]

				J. Beyer, S. Stenning, A. Gerl, S. Fossa, and W. Siegert High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis Ann. Onc., April 1, 2002; 13(4): 599 - 605. [Abstract] [Full Text] [PDF]

				J. Vuky, S. K. Tickoo, J. Sheinfeld, J. Bacik, A. Amsterdam, M. Mazumdar, V. Reuter, D. F. Bajorin, G. J. Bosl, and R. J. Motzer Salvage Chemotherapy for Patients With Advanced Pure Seminoma J. Clin. Oncol., January 1, 2002; 20(1): 297 - 301. [Abstract] [Full Text] [PDF]

				D. T. Schneider, R. Wessalowski, G. Calaminus, H. Pape, M. Bamberg, J. Engert, K. Waag, H. Gadner, and U. Gobel Treatment of Recurrent Malignant Sacrococcygeal Germ Cell Tumors: Analysis of 22 Patients Registered in the German Protocols MAKEI 83/86, 89, and 96 J. Clin. Oncol., April 1, 2001; 19(7): 1951 - 1960. [Abstract] [Full Text] [PDF]

				F. Rabbani, J. Sheinfeld, H. Farivar-Mohseni, A. Leon, M. J. Rentzepis, V. E. Reuter, H. W. Herr, J. A. McCaffrey, R. J. Motzer, D. F. Bajorin, et al. Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse J. Clin. Oncol., April 1, 2001; 19(7): 2020 - 2025. [Abstract] [Full Text] [PDF]

				O. Rick, C. Bokemeyer, J. Beyer, J. T. Hartmann, N. Schwella, D. Kingreen, S. Neureither, B. Metzner, J. Casper, H. Wandt, et al. Salvage Treatment With Paclitaxel, Ifosfamide, and Cisplatin Plus High-Dose Carboplatin, Etoposide, and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer J. Clin. Oncol., January 1, 2001; 19(1): 81 - 88. [Abstract] [Full Text] [PDF]

				R. J. Motzer, J. Sheinfeld, M. Mazumdar, M. Bains, T. Mariani, J. Bacik, D. Bajorin, and G. J. Bosl Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer J. Clin. Oncol., June 12, 2000; 18(12): 2413 - 2418. [Abstract] [Full Text] [PDF]

				R. J. Motzer, M. Mazumdar, J. Sheinfeld, D. F. Bajorin, H. A. Macapinlac, M. Bains, L. Reich, C. Flombaum, T. Mariani, W. P. Tong, et al. Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients J. Clin. Oncol., March 13, 2000; 18(6): 1173 - 1180. [Abstract] [Full Text] [PDF]